About our B7-H6/CD3 T-cell engager
Mechanism of action
Our B7-H6/CD3 T-cell engager simultaneously binds to cluster of differentiation 3 (CD3) expressed on T cells and B7-H6 expressed on tumor cells resulting in formation of a cytolytic synapse and redirection of the cytolytic activity of T cells towards tumor cells that express B7-H6. Consistent with the mode-of-action, the treatment with B7-H6/CD3 T-cell engager in vivo leads to tumor cell apoptosis, local activation and proliferation of T cells, and cytokine secretion in the tumor tissue, converting a non-inflamed (cold) tumor environment into an inflamed (hot) tumor environment.1
T-cell engager mechanism of action1
CD3, cluster of differentiation 3.
Watch the T-cell engager mechanism of action animation
Combination therapy
In humanized CRC mouse models, monotherapy with our B7-H6/CD3 T-cell engager resulted in tumor regression which was associated with local activation and proliferation of T cells, secretion of cytokines, and upregulation of the PD-(L)1 pathway in the tumor tissue; therefore, combination with anti-PD-1 agents (such as ezabenlimab) may further enhance the efficacy of the B7-H6/CD3 T-cell engager.1,2
Boehringer Ingelheim. Data on file.
Hipp S, et al. Cancer Res. 2021;81(13 Supplement):56. DOI: 10.1158/1538-7445.AM2021-56.